Prof. Dr. Senem KARABULUT

A. Uluslararası hakemli dergilerde yayımlanan makaleler:
A.1 Karabulut Senem, Duranyıldız Derya, Tas Faruk, Gezer Ugur, Akyüz Filiz, Serilmez Murat, Ozgür Emre, Yasasever Tilgen Ceren, Vatansever Sezai, Aykan Nuri Faruk (2014). Clinical Significance of Serum Circulating Insulin-Like Growth Factor-1 (IGF-1) mRNA in Hepatocellular Carcinoma. Tumour Biol, 35(3), 2729-39. Doi: 10.1007/s13277-013-1360-4.
A.2 Karabulut Senem, Akşit Ece, Tas Faruk, Ciftci Rümeysa, Aydiner Adnan, Yildiz Ibrahim, Keskin Serkan, Eralp Yeşim, Yasasever Tilgen Ceren, Vatansever Sezai, Disci Rian, Saip Pınar (2014). Is There Any Diagnostic Value of Serum Protease-Activated Receptor-1 (PAR1) Levels on Determination of Epithelial Ovarian Carcinoma? Tumour Biol, 35(5), 4323-9. Doi: 10.1007/s13277-013-1567-4.
A.3 Karabulut Senem, Tas Faruk, Tastekin Didem, Karabulut Mehmet, Yasasever Tilgen Ceren, Ciftci Rümeysa, Güveli Murat, Fayda Merdan, Vatansever Sezai, Serilmez Murat, Disci Rian, Aydıner Adnan (2014). The Diagnostic, Predictive, and Prognostic Role of Serum Epithelial Cell Adhesion Molecule (EPCAM) and Vascular Cell Adhesion Molecule-1 (VCAM-1) Levels in Breast Cancer. Tumour Biol, 35(9), 8849-60. Doi: 10.1007/s13277-014-2151-2.
A.4 Karabulut Senem, Usul Afsar Cigdem, Karabulut Mehmet, Kilic Leyla, Alis Halil,Kones Osman, Bilgin Elif, Aykan Nuri Faruk (2016). Clinical Significance of Serum Interleukin-17 Levels in Colorectal Cancer Patients. Journal of Balkan Union of Oncology (JBUON), 21(5), 1137-1145.
A.5 Karabulut Senem, Afsar Usul Cigdem, Karabulut Mehmet, Alis Halil, Binboğa Sinan, Bilgin Elif, Tas Faruk (2016). Circulating Macrophage Inflamatuar Protein-1 Alfa (MIP1- Α) As A Potential Biomarker for The Diagnosis of Patients with Pancreatic Adenocarcinoma. Acta Medica Mediterranea, 32, 463-68.

A.6 Karabulut Senem, Afsar Usul Cigdem, Karabulut Mehmet, Alis Halil, Erturk Kayhan, Karaman Sule, Könes Osman, Bilgin Elif, Tas Faruk (2016). Serum Leptin Levels May Have Diagnostic and Predictive Roles in Patients with Pancreatic Adenocarcinoma Treated with Gemcitabine-Based Chemotherapy. Journal of Balkan Union of Oncology (JBUON), 21(4), 895-902.
A.7 Karabulut Senem, Tas Faruk, Akyüz Filiz, Ormeci Ciftcibası Aslı, Serilmez Murat, Soydinç Oguz Hilal, Vatansever Sezai, Yasasever Vildan (2014). Clinical Significance of Serum Hepatocyte Growth Factor (HGF) Levels in Hepatocellular Carcinoma. Tumour Biol, 35(3), 2327-33. Doi: 10.1007/s13277-013-1308-8.
A.8 Karabulut Senem, Afsar Usul Cigdem, Karabulut Mehmet, Alış Halil, Kılıc Leyla, Çikot Murat, Yasasever Tilgen Ceren, Aykan Nuri Faruk (2016). Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma. J Gastrointest Cancer, 47(1), 47-54. Doi: 10.1007/s12029-015-9787-z.
A.9 Karabulut Senem, Keskin Serkan, Ekenel Meltem, Basaran Mert, Agaoglu Fulya Ozger Harzem, Bavbek Sevil (2013). The Clinical Effect of a Positive Surgical Margin and Adjuvant Postoperative Radiotherapy in The Treatment of Resectable Desmoid Tumors. Mol Clin Oncol, 1(6), 1061-64.
A.10 Karabulut Senem, Usul Afsar Cigdem, Karabulut Mehmet, Alis Halil, Bozkurt Mehmet Abdussamet, Aydogan Fatma, Serilmez Murat, Tas Faruk (2016). Clinical Significance of Serum Omentin-1 Levels in Patients with Pancreatic Adenocarcinoma. BBA Clin, 6, 138-142.
A.11 Erdogan Bülent, Kodaz Hilmi, Karabulut Senem, Cinkaya Ahmet, Tozkir Hilmi, Tanriverdi Ozgur, Cabuk Devrim, Hacioglu Muhammed Bekir, Turkmen Esma, Hacibekiroglu Ilhan, Uzunoglu Sernaz, Cicin Irfan (2016). Impact of Active Smoking On Survival Of Patients With Metastatic Lung Adenocarcinoma Harboring An Epidermal Growth Factor Receptor (EGFR) Mutation. Bosn J Basic Med Sci.16 (4): 280-285. Doi: 10.17305/bjbms.2016.1380.
A.12 Artaç Mehmet, Coşkun Hasan Şenol, Dane Faysal, Karabulut Bülent, Korkmaz Levent, Karaağaç Mustafa, Çabuk Devrim, Karabulut Senem, Faruk Aykan Nuri, Doruk Hatice, Avcı Nilüfer, Turhal Nazım Serdal (2016). Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. J Gastrointest Cancer, 47(3), 264-272. Doi: 10.1007/s12029-016-9823-7.
A.13 Tas Faruk, Karabulut Senem, Ciftci Rümeysa, Yildiz Ibrahim, Keskin Serkan, Kilic Leyla, Disci Rian (2014). The Behavior of Turkish Cancer Patients in Fasting During the Holy Month of Ramadan. Jpn J Clin Oncol, 44(8), 705-10. Doi: 10.1093/jjco/hyu070.
A.14 Tas Faruk, Karabulut Senem, Ciftci Rümeysa, Sen Fatma, Sakar Burak, Disci Rian, Duranyildiz Derya (2014). Serum Levels of LDH, CEA, and CA19-9 Have Prognostic Roles on Survival in Patients with Metastatic Pancreatic Cancer Receiving Gemcitabine-Based Chemotherapy. Cancer Chemother Pharmacol, 73(6), 1163-71. Doi: 10.1007/s00280-014-2450-8.
A.15 Keskin Serkan, Tas Faruk, Karabulut Senem, Yildiz Ibrahim, Kiliç Leyla, Ciftci Rümeysa, Vatansever Sezai (2013). The Role of Surgical Methods in The Treatment of Anorectal Malignant Melanoma (AMM). Acta Chir Belg, 113(6), 429-33.
A.16 Tas Faruk, Ciftci Rümeysa, Kilic Leyla, Karabulut Senem (2013). Age Is A Prognostic Factor Affecting Survival in Lung Cancer Patients. Oncol Lett, 6(5): 1507-13.
A.17 Keskin Serkan, Tas Faruk, Ekenel Meltem, Kilic Leyla, Sen Fatma, Yildiz Ibrahim, Karabulut Senem, Ciftci Rümeysa, Vatansever Sezai (2013). Biweekly Triplet Chemotherapy with Gemcitabine, Cisplatin and Vinorelbine for Advanced Chemotherapy Naïve Non-Small Cell Lung Cancer. Tumori, 99(4), 463-8. Doi: 10.1700/1361.15095
A.18 Aydiner Adnan, Ciftci Rümeysa, Karabulut Senem, Kilic Leyla (2013). Does Beta-Blocker Therapy Improve The Survival of Patients with Metastatic Non-Small Cell Lung Cancer? Asian Pac J Cancer Prev, 14(10), 6109-14.
A.19 Faruk Aykan Nuri, Yildiz Ibrahim, Sen Fatma, Kilic Leyla, Keskin Serkan, Ciftci Rümeysa, Karabulut Senem, Sakar Burak, Disci Rian (2013). Effect of İncreased Body Mass İndex (BMI) on Time to Tumour Progression (TTP) in Unresectable Metastatic Colorectal Cancer (mCRC) Patients Treated with Bevacizumab-Based Therapy. Med Oncol, 30(3), 679. Doi: 10.1007/s12032-013-0679-4.
A.20 Keskin Serkan, Ciftci Rümeysa, Karabulut Senem, Kucucuk Seden, Yildiz Ibrahim, Kilic Leyla, Eralp Yeşim, Saip Pınar (2013). The Frequencies of Breast Cancer (BC) in Extreme Ages Changing Over Time. Mediterranean Oncology Journal, 1, 53-55.
A.21 Karabulut Mehmet, Alış Halil, Günaldı Meral, Afsar Usul Ciğdem, Karabulut Senem, Köneş Osman, Seyit Hakan, Serilmez Murat, Aykan Nuri Faruk (2016). Clinical Significance of Serum Hepatocyte Growth Factor (HGF) and Its Receptor C-MET Levels Colorectal Cancer Patients. Acta Medica Mediterranea, 32: 179-187. Doi: 10.19193/0393-6384-2016-1-28.
A.22 Karabulut Mehmet, Gunaldi Meral, Alis Halil, Afsar Usul Cigdem, Karabulut Senem, Serilmez Murat, Akarsu Cevher, Seyit Hakan, Aykan Nuri Faruk (2016). Serum Nectin-2 Levels Are Diagnostic and Prognostic in Patients with Colorectal Carcinoma. Clin Transl Oncol, 18(2) ,160-71. Doi: 10.1007/s12094-015-1348-1.
A.23 Kilic Leyla, Yildiz Ibrahim, Sen Karagöz Fatma, Erdem Mustafa Genco, Serilmez Murat, Keskin Serken, Ciftci Rümeysa, Karabulut Senem, Ordu Cetin, Duranyildiz Derya, Tas Faruk (2015). D-dimer and International Normalized Ratio (INR) Are Correlated with Tumor Markers and Disease Stage in Colorectal Cancer Patients. Cancer Biomark. 15(4), 405-11. Doi: 10.3233/CBM-150477
A.24 Tas Faruk, Karabulut Senem, Serilmez Murat, Karabulut Mehmet, Duranyildiz Derya (2015). Elevated Circulating Monocyte Chemoattractant Protein 1 (MCP-1/CCL-2) Level May Be An Unfavorable Predictive Factor To Platinum-And Taxane-Based Combination Chemotherapy İn Patients With Gastric Cancer. Cancer Chemother Pharmacol. 77 (1), 127-131. Doi:10.1007/s00280-015-2886-5.

A.25 Karabulut Mehmet, Alis Halil, Afsar Usul Cigdem, Karabulut Senem, Kocatas Ali, Oguz Hilal, Aykan Nuri Faruk (2015). Serum Neural Precursor Cell-Expressed, Developmentally Down Regulated 9 (NEDD9) Level May Have A Prognostic Role İn Patients With Gastric cancer. Biomed Pharmacother, 73, 140-6. Doi: 10.1016/j.biopha.2015.06.010.
A.26 Tas Faruk, Yasasever Tilgen Ceren, Karabulut Senem, Tastekin Didem, Duranyildiz Derya (2015). Clinical Significance of Serum Interleukin-18 (IL-18) Levels in Patients with Gastric Cancer. Biomed Pharmacother.70, 19-23. Doi: 10.1016/j.biopha.2014.12.040.
A.27 Tas Faruk, Yasasever Tilgen Ceren, Karabulut Senem, Tastekin Didem, Duranyildiz Derya (2015). Circulating Annexin A2 as a Biomarker in Gastric Cancer Patients: Correlation with Clinical Variables. Biomed Pharmacother, 69, 237-41. Doi: 10.1016/j.biopha.2014.12.005.
A.28 Tas Faruk, Yasasever Tilgen Ceren, Karabulut Senem, Tastekin Didem, Duranyildiz Derya (2015). SerumTransforming Growth Factor-Beta1 Levels May Have Predictive and Prognostic Roles in Patients with Gastric Cancer. Tumour Biol, 36(3), 2097-103. Doi: 10.1007/s13277-014-2817-9.
A. 29 Tas Faruk, Bilgin Elif, Karabulut Senem, Duranyildiz Derya (2015). Clinical Significance of Serum Epidermal Growth Factor Receptor (EGFR) Levels In Patients With Breast Cancer. Cytokine, 71(1), 66-70. Doi: 10.1016/j.cyto.2014.09.001.
A.30 Tas Faruk, Karabulut Senem, Yildiz Ibrahim, Duranyildiz Derya (2014). Clinical Significance of Serum M30 and M65 Levels in Patients with Breast Cancer. Biomed Pharmacother, 68(8), 1135-40. Doi: 10.1016/j.biopha.2014.10.021.
A.31 Tas Faruk, Karabulut Senem, Bilgin Elif, Tastekin Didem, Duranyildiz Derya (2014). Clinical Significance of Serum Fibronectin and Vitronectin Levels in Melanoma Patients. Melanoma Res. 24(5), 475-9. Doi: 10.1097/CMR.0000000000000107.
A.32 Tas Faruk, Karabulut Senem, Bilgin Elif, Tastekin Didem, Duranyildiz Derya (2014). Clinical Significance of Serum Insulin-Like Growth Factor-1 (IGF-1) and Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) in Patients with Breast Cancer. Tumour Biol. 35(9), 9303-9. Doi: 10.1007/s13277-014-2224-2.
A.33 Tas Faruk, Karabulut Senem, Bilgin Elif, Duranyildiz Derya. Serum Levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) May Have Diagnostic, Predictive, and Prognostic Roles in Patients with Lung Cancer Treated with Platinum-Based Chemotherapy (2014). Tumour Biol. 35(8), 7871-5. Doi: 10.1007/s13277-014-2050-6.
A.34 Tas Faruk, Karabulut Senem, Yasasever Tilgen Ceren, Duranyildiz Derya (2014). Serum Transforming Growth Factor-Beta 1 (TGF-Β1) Levels Have Diagnostic, Predictive, and Possible Prognostic Roles in Patients with Melanoma. Tumour Biol, 35(7), 7233-7. Doi: 10.1007/s13277-014-1984-z.

A.35 Ciftci Rümeysa, Tas Faruk, Yasasever Tilgen Ceren, Aksit Ece, Karabulut Senem, Sen Fatma, Keskin Serkan, Kilic Leyla, Yildiz Ibrahim, Bozbey Hamza Ugur, Duranyildiz Derya, Vatansever Sezai (2014). High Serum Transforming Growth Factor Beta 1 (TGFB1) Level Predicts Better Survival in Breast Cancer. Tumour Biol, 35(7), 6941-8. Doi: 10.1007/s13277-014-1932-y.
A.36 Tastekin Didem, Tas Faruk, Karabulut Senem, Duranyildiz Derya, Serilmez Murat, Guveli Murat, Vatansever Sezai (2014). Clinical Significance of Serum Tenascin-C Levels in Breast Cancer. Tumour Biol, 35(7), 6619-25. Doi: 10.1007/s13277-014-1875-3.
A.37 Tas Faruk, Karabulut Senem, Serilmez Murat, Ciftci Rümeysa, Duranyildiz Derya (2014). Increased Serum Level of Epidermal Growth Factor Receptor (egfr) is Associated with Poor Progression-Free Survival in Patients with Epithelial Ovarian Cancer. Cancer Chemother Pharmacol, 73(3), 631-7. Doi: 10.1007/s00280-014-2396-x.
A.38 Varol Basak, Coşkun Özlem, Karabulut Senem, Serin Kürsat Rahmi, Asoğlu Oktar, Albeniz Isıl, Taş Faruk, Nurten Rustem (2014). Clinical Significance Of Serum Adp-Ribosylation And Nad Glycohydrolase Activity in Patients with Colorectal Cancer. Tumour Biol, 35(6), 5575-82. Doi: 10.1007/s13277-014-1735-1.
A.39 Tas Faruk, Karabulut Senem, Serilmez Murat, Ciftci Rümeysa, Duranyildiz Derya (2014). Serum Levels of Macrophage Migration-İnhibitory Factor (MIF) Have Diagnostic, Predictive and Prognostic Roles in Epithelial Ovarian Cancer Patients. Tumour Biol, 35(4), 3327-31. Doi: 10.1007/s13277-013-1438-z.
A.40 Tas Faruk, Karabulut Senem, Serilmez Murat, Ciftci Rümeysa, Duranyildiz Derya (2014). Clinical Significance of Serum Transforming Growth Factor-Beta 1 (TGF-Β1) Levels in Patients With Epithelial Ovarian Cancer. Tumour Biol, 35(4), 3611-6. Doi: 10.1007/s13277-013-1476-6.
A.41 Tas Faruk, Karabulut Senem, Serilmez Murat, Ciftci Rümeysa, Duranyildiz Derya (2014). Clinical Significance of Serum İnsulin-Like Growth Factor-1 (IGF-1) and İnsulinlike Growth Factor Binding Protein-3 (IGFBP-3) in Patients With Epithelial Ovarian Cancer. Tumour Biol, 35(4), 3125-32. Doi: 10.1007/s13277-013-1405-8.
A.42 Didem Tastekin, Faruk Tas, Senem Karabulut, Derya Duranyıldız, Murat Serilmez, Murat Güveli, Oznur Kaynur (2014). Clinical Significance of Serum Tenascin-C Levels in Epithelial Ovarian Cancer. Tumour Biol, 35(7), 6777-82. Doi: 10.1007/s13277-014-1923-z.
A.43 Tas Faruk, Karabulut Senem, Serilmez Murat, Yildiz Ibrahim, Sen Fatma, Ciftci Rümeysa, Duranyildiz Derya (2013). Clinical Significance of Serum M30 And M65 Levels in Melanoma. Melanoma Res. Doi: 10.1097/CMR.0b013e328363e4ab.
A.44 Yildiz Ibrahim, Tas Faruk, Kilic Leyla, Sen Fatma, Saip Pınar, Eralp Yesim, Keskin Serkan, Karabulut Senem, Ciftci Rümeysa, Serilmez Murat, Yasasever Vildan, Aydiner Adnan (2013). A High Serum Level of M65 is Associated with Tumour Aggressiveness and An Unfavourable Prognosis for Epithelial Ovarian Cancer. Cancer Chemother Pharmacol, 72(2), 437-44. Doi: 10.1007/s00280-013-2212-z.

A.45 Tas Faruk, Karabulut Senem, Bilgin Elif, Sen Fatma, Yildiz Ibrahim, Tastekin Didem, Ciftci Rümeysa, Duranyildiz Derya (2013). Clinical Significance of Serum M30 and M65 Levels in Metastatic Pancreatic Adenocarcinoma. Tumour Biol, 34(6), 3529-36. Doi: 10.1007/s13277-013-0931-8.
A.46 Tas Faruk, Karabulut Senem, Tastekin Didem, Duranyildiz Derya (2016). Clinical significance of serum protease-activated receptor-1 levels in gastric cancer patients. Biomed Rep, 4(4), 489-492.
A.47 Tas Faruk, Karabulut Senem, Yasasever Tilgen Ceren, Duranyildiz Derya (2016). Clinical Significance of Serum Caveolin-1L levels in Melanoma Patients. Int J Dermatol, ;55(5), 558-62. Doi: 10.1111/ijd.12862.
A.48 Tas Faruk, Karabulut Senem, Duranyildiz Derya. Clinical Significance Of Serum Epithelial Cell Adhesion Molecule (Epcam) Levels İn Patients With Lung Cancer (2014). Mol Cell Biochem, 396(1-2), 307-12. Doi: 10.1007/s11010-014-2167-3.
A.49 Tas Faruk, Karabulut Senem, Bilgin Elif, Kılıc Leyla, Ciftci Rümeysa, Duranyildiz Derya (2013). Clinical Significance of Coagulation Assays In Metastatic Pancreatic Adenocarcinoma. J Gastrointest Cancer, 44(4), 404-9. Doi: 10.1007/s12029-013-9512-8.
A.50 Tas Faruk, Ciftci Rümeysa, Kilic Leyla, Serilmez Murat, Karabulut Senem, Duranyildiz Derya (2013). Clinical and Prognostic Significance of Coagulation Assays in Gastric Cancer. J Gastrointest Cancer, 44(3), 285-92. Doi: 10.1007/s12029-013-9490-x.
A.51 Tas Faruk, Bilgin Elif, Karabulut Senem, Duranyildiz Derya (2016). Clinical Significance of Serum Laminin and Type-IV Collagen Levels in Cutaneous Melanoma Patients. Mol Clin Oncol., 5(1), 195-200. Doi:10.3892/mco.2016.873
A.52 Tas Faruk, Bilgin Elif, Karabulut Senem, Erturk Kayhan, Duranyildiz Derya (2016). Clinical Significance of Serum Protease-Activated Receptor-1 (PAR-1) Levels in Patients with Cutaneous Melanoma. BBA Clin., 5, 166-9. Doi: 10.1016/j.bbacli.2016.04.001.
A.53 Tas Faruk, Bilgin Elif, Karabulut Senem, Tastekin Didem, Duranyildiz Derya (2016). Levels of Serum Fibronectin as a Biomarker in Gastric Cancer Patients: Correlation with Clinical Diagnosis and Outcome. Mol Clin Oncol, 4(4), 655-659.
A.54 Karabulut Mehmet, Alis Halil, Bas Koray, Karabulut Senem, Afsar Usul Cigdem, Oguz Hilal, Gunaldi Meral, Akarsu Cevher, Kones Osman, Aykan Nuri Faruk (2015). Clinical Significance of Serum Cclaudin-1 and Claudin-7 Levels in Patients with Colorectal Cancer. Mol Clin Oncol, 3(6), 1255-1267.
A. 55 Afsar Usul Cigdem, Karabulut Mehmet, Karabulut Senem, Alis Halil, Gonenc Murat, Dagoglu Nergiz, Serilmez Murat, Tas Faruk (2016). Circulating Interleukin-18 (Il-18) Is A Predictor of Response to Gemcitabine Based Chemotherapy in Patients with Pancreatic Adenocarcinoma. Journal of Infection and Chemotherapy, 23 (4), 196-200.
A.56 Kılıç Leyla, Ekenel Meltem, Karabulut Senem, Ağaoğlu Fulya, Darendeliler Emin (2017). Neoadjuvant Sequential Chemoradiotherapy Versus Radiotherapy Alone For Treatment Of High Risk Extremity Soft Tissue Sarcoma: A Single Institution Experience. Contemporary Oncology, 21 (1), 60-65
A.57 Tas F, Karabulut S, Serilmez M, Ciftci Rümeysa, Duranyildiz Hadiye Derya (2014). Clinical Significance of Serum Epithelial Cell Adhesion Molecule (Epcam) and Vascular Cell Adhesion Molecule-1 (Vcam-1) Levels in Patients with Epithelial Ovarian Cancer. Tumor Biology, 35 (4), 3095-3102. Doi: 10.1007/s13277-013-1401-z
A.58 Çiftçi Rümeysa, Tas Faruk, Karabulut Senem, Ciftci Serkan (2015). Combination of Capecitabine and Phenytoin May Cause Phenytoin Intoxication: A Case Report. Am J Ther, 22(1), e17-9. Doi: 10.1097/MJT.0b013e318293b10a
A.59 Tas Faruk, Karabulut Senem, Yegen Gülcin, Onder Semen, Ciftci Rümeysa (2015). Tongue Metastasis of Melanoma. J Cancer Res Ther, 11(3), 660. Doi: 10.4103/0973-1482.139526.
A.60 Tas Faruk, Ciftci Rümeysa, Buyukbabani Nesimi, Karabulut Senem (2014). Recurrent Gastric Cancer Presenting with Both Scrotal and Facial Skin Metastases: A Case Report. J Gastrointest Cancer, 45(1), 96-9. Doi: 10.1007/s12029-013-9484-8
A.61 Tas F, Karabulut S, Guveli H, Kurul S, Erturk K, Guveli M, Kinik H (2017). Assessment of Anxiety and Depression Status in Turkish Cutaneous Melanoma Patients. Asian Pac J Cancer Prev. 18(2): 369-373.
A.62 Feryal Karaca, Cıgdem Usul Afsar, Necat Almalı, Senem Karabulut, Mehmet Karabulut, Sıddık Keskin, Serkan Akbulut (2017). The Effect of Pretreatment Neutrophil/Leucocyte Ratio on Survival in Patientrs with Locally Advanced Esophageal Cancer Receving Chemoradiotherapy. Acta Medica Mediterranea, 33: 863-869.
A.63 Cıgdem Usul Afsar, Mehmet Karabulut, Senem Karabulut, Halıl Alıs, Sınan Bınboga, Elıf Bılgın, Nurı Faruk Aykan (2017). Circulatıng Monocyte Chemoattractant Proteın-1 (MCP-1/CCL-2) As a Potentıal Bıomarker for The Dıagnosıs of Pancreatıc Adenocarcınoma. Acta Medica Mediterranea, 33: 501-507
A.64 Mehmet Karabulut, Cıgdem Usul Afsar, Senem Karabulut, Peker Kıvanc Derya, Gemici Eyüp, Dağoğlu Nergis, Karaman Şule, Yasasever Tilgen Ceren, Taş Faruk (2017). Serum Interleukin-32 (il-32) Levels May Have Diagnostic and Prognostic Roles in Patients with Pancreatic Adenocarcinoma. Acta Medica Mediterranea, 33: 613-61.
A.65 Artaç M, Korkmaz L, Coşkun HŞ, Dane F, Karabulut B, Karaağaç M, Çabuk D, Karabulut S, Aykan NF, Doruk H, Avcı N, Turhal NS (2018). Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients. J Gastrointest Cancer. Doi: 10.1007/s12029-017-0047-2.
A.66 Tas F, Karabulut S, Erturk K, Duranyildiz D (2018). Clinical Significance of Serum Leptin Level in Patients with Gastric Cancer. Eur Cytokine Netw. 29 (2): 52-58. Doi: 10.1684/ecn.2018.0408.
A.67 Korkmaz L, Coşkun HŞ, Dane F, Karabulut B, Karaağaç M, Çabuk D, Karabulut S, Aykan NF, Doruk H, Avcı N, Turhal NS, Artaç M (2018). Kras-mutation İnfluences Outcomes for Palliative Primary Tumor Resection in Advanced Colorectal Cancer- A Turkish Oncology Group Study. Surg Oncol. 27(3): 485-489. Doi: 10.1016/j.suronc.2018.05.032.

A.68 Mehmet Karabulut, Cigdem Usul Afsar, Halil Alis, Ebru Oran, Senem Karabulut, Cevher Akarsu, Nuri Alper Sahbaz, Elif Bilgin, Nuri Faruk Aykan (2017). Evaluation of Epidermal Growth Factor Receptor Serum Levels and Their Associations with Clinicopathological Characteristics in Patients with Colorectal Cancer. Moleculer and Clinical Oncology 7 (5): 787-797. Doi: 10.3892/mco.2017.1405
A.69 Tas F, Karabulut S, Erturk K, Duranyildiz D (2018).Clinical Significance of Serum Caveolin-1 Levels in Gastric Cancer Patients. Exp Oncol. 40(4):323-327.
A.70 Cigdem Usul Afsar, Mehmet Karabulut, Senem Karabulut, Safiye Tokgoz Ozal, Murat Cikot, Murat Serilmez, Faruk Tas (2018). Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer. Biomolecules 8: 169. Doi:10.3390/biom8040169
A.71 Süleyman Bademler, Murat Sarı, Muhammet Zubeyr Üçünçü, Murat Serilmez, Senem Karabulut (2018). Clinical Significance of Serum Insülin-Like Growth Factor-1 (IGF-1) and Insülün Like Growth Binding Protein- 3 (IGFBP-3) in Patients with Gastric Cancer. Acta Medica Mediterranea 34: 2055-2060 DOI: 10.19193/0393-6384_2018_6_320
A.72 Bademler S, Zirtiloglu A, Sarı M, Ucuncu MZ, Dogru EB, Karabulut S (2019). Clinical Significance of Serum Membrane-Bound Mucin-2 Levels in Breast Cancer. Biomolecules. 9(2): 40. Doi: 10.3390/biom9020040.
A.73 Süleyman Bademler, Alişan Zirtiloğlu, Murat Sarı, Ceren Tilgen Yasasever, Senem Karabulut (2019). IGF-1and IGFBP-3 in Colorectal Cancer, an Observational Case-Control Study. Acta Medica Mediterranea, 35: 15 DOI: 10.19193/0393-6384_2019_1_1
A.74 Murat Üçüncü, Murat Serilmez, Murat Sarı, Süleyman Bademler, Senem Karabulut (2019). The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer. Biomolecules. 9(9). pii: E464. doi: 10.3390/biom9090464.
A.75 Mehmet Karabulut, Cigdem Usul Afsar, Murat Serilmez, Senem Karabulut (2019). Serum IL-17 levels can be diagnostic for gastric cancer. J BUON. 24(4):1601-1609.
A.76 Meltem Ekenel, Senem Karabulut, İbrahim Cil, Alişan Zırtıloğlu, Esra Aydın, Deniz Tural (2019). Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience. Actas Urol Esp. pii: S0210-4806(19)30148-2. doi: 10.1016/j.acuro.2019.06.007.
A.77 Gözde Kuru Türkcan, Demet Akdeniz Ödemiş, Mukaddes Avşar, Şeref Buğra Tunçer, Seda Kılıc Erciyas, Özge Şükrüoğlu Erdoğan, Didem Taştekin, Senem Karabulut, Esra Kaytan, Hülya Yazıcı (2019). The Association of Pancreatic Cancer and PALB2 Gene Mutations in the Turkish Population. Turk J Oncol 34(3):283–90 doi: 10.550 5/tjo.2019.1948
A.78 Esra Arslan, Hale Aral, Tamer Aksoy, Çiğdem Usul Afşar, Senem Karabulut, Fadime Didem Can Trabulus, Rıza Umar Gürsu, Tevfik Fikret Çermik (2020) Comparison of serum NEDD-9, CA 15-3, and CEA levels and PET metabolic parameters in breast cancer patients with 18 F-FDG PET / CT Rev Assoc Med Bras (1992). 66(5):673-79. doi: 10.1590/1806-9282.66.5.673.

A.79 Senem Karabulut, Izzet Dogan, Cıgdem Usul Afsar, Mehmet Karabulut, Sule Karaman, Ferhat Ferhatoglu, Didem Taştekin (2020). Does nutritional status affect treatment tolerability, response and survival in metastatic colorectal cancer patients? Results of a prospective multicenter study Journal of Oncology Pharmacy Practice, 27 (6): 1357-1363. Doi: 10.1177/1078155220959427
A.80 Mehmet Karabulut, Usul Afsar Cigdem, Murat Serilmez, Senem Karabulut (2020). Circulating annexin A2 as a biomarker in patients with pancreatic cancer. Journal of Cancer Research and Therapeutics. Doi: 10.4103/jcrt.JCRT_755_18
A.81 Karabulut S, Dogan I, Usul Afsar C, Karabulut M, Ak N, Duran A, Tastekin D (2021). Does nutritional status affect treament tolerability, chemotherapy response and survival in metastatic gastric cancer patients? Results of a prospective multicenter study in Turkey. Journal of Oncology Pharmacy Practice, 28 (1):127-134. Doi: 10.1177/1078155220987291
A.82 Serin KR, Ucuncu MZ, Temel MK, Bademler S, Soydinc Oguz H, Karanlık H, Karabulut S (2021). Clinical utility of Tensin 2 level as a diagnostic and prognostic biomarker in breast cancer. Acta Medica Mediterranea, 37: 553-558. DOI 10.19193/0393-6384_2021_1_86
A.83 Yekedüz E, Doğan I, Birgi SD, Keskin M, Karaman S, Utkan G, Karabulut S, Bayar S, Akbulut H, Demirci S, Akyürek S, Ürün Y (2021). Adjuvant treatment of gastric cancer in the D2 dissection era: A real life experience from a multicenter retrospective cohort study. Euroasian Journal of Hepato-Gastroenterology. 11 (2): 51-58.
A.84 Özkan GZ, Şimşek Has D, Kuyumcu S, Oflas M, Işik Göknur E, Dogan I, Karabulut S, Şanlı Y (2021). Prognostic value of FDG PET-CT in suspect recurrence of colorectal carcinoma: survival outcomes of 10 –year follow up. Annals of Nuclear Medicine. Doi: 10.1007/s12149-021-01684-7
A.85 Tastekin D, Paksoy N, Dogan I, Ferhatoglu F, Khanmammadov N, Karabulut S (2023). Fluorouracil, Leucoverin, Oxaliplatin, and Docetaxel (FLOT) Regimen in the First-Line Treatment of Metastaic Gastric Cancer: A Single Center Experiences. Journal of Cancer Research and Therapeutics. DOI: 10.4103/jcrt.jcrt_672_22
A86. Karabulut S, Topalgökceli Selam M, Tastekin D. Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers. EJMO 2022; 6 (1): 12-15. DOİ: 10.14744/ejmo. 2022. 74316
A87. Dogan I, Karabulut S, Tastekin D, Ferhatoglu F, Paksoy N, Sakar B. Evaluation of Prognostic Factors and Trastuzumab-based Treatments in Her2/Neu-positive Metastatic Gastric Cancer. J Coll Physicians Surg Pak 2022; 32(8):1014-1019
A88. Dogan I, Gurbuz M, Aydin E, Karabulut S, Tastekin D, Utkan G. Distributions and Prognostic Effects of ABO/Rh Blood Groups in Patients with HER2/neu Posittive Gastric and Gastroesophageal Junction Cancer. Journal of Cancer Research and Therapeutics. DOI: 10.4103/jcrt.jcrt_1520_22
A89. Izzet Dogan, Didem Tastekin, Senem Karabulut, Burak Sakar (2022). Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors. J Dig Dis. 2022; 23: 493–499.Doi: 10.1111/1751-2980.13123.
A 90. Cihan Erol, Abdullah Sakin, Tuğba Başoğlu, Ercan Özden, Devrim Çabuk, Mutlu Doğan, Berna Öksüzoğlu, Hasan Çağrı Yıldırım, İrem Öner, Melek Karakurt Eryılmaz, Özgecan Dülgar, Dinçer Aydın, Neslihan Doğan, Miraç Özen, İlhan Hacıbekiroğlu, Nuriye Özdemir, Fatih Gürler, Nail Paksoy, Senem Karabulut, Asude Aksoy, Mutlu Hızal, Seda Kahraman, Erdem Şen, Semra Paydaş, Ebru Çılbır, Feyza Fırat, Nadiye Akdeniz, Melike Özçelik, Abdilkerim Oyman , Naziyet Köse Baytemür, Ramazan Acar, Elvina Almuradova, Bülent Karabulut, Teoman Şakalar, Hacı Arak, Ezgi Değerli, Sema Türker, Özkan Alan, Özlem Er, Elif Şenocak Taşçı, Nazan Demir, Eyyüp Çavdar, Serdar Turhal, Didem Şener Dede, Muhammed Bülent Akıncı, Bülent Yalçın, Fulden Yumuk, Şuayib Yalçın, Mehmet Ali Nahit Şendur (2022). Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group). Turk J Med Sci; 2022; 52(4): 1022-1032. doi: 10.55730/1300-0144.5404.
A 91. Muhammet Bekir Hacioglu, Osman Kostek, Senem Karabulut, Didem Tastekin, Sema Sezgin Goksu, Celal Alandag, Baran Akagunduz, Irem Bilgetekin, Burcu Caner, Ahmet Bilgehan Sahin, Birol Yildiz, Fatih Kose, Muhammet Ali Kaplan, Ahmet Gulmez, Ender Dogan, Deniz Can Guven, Mustafa Gurbuz, Yakup Ergun, Mustafa Karaagac, Atike Gokcen Demiray, Sema Turker1 Teoman Sakalar, Ozlem Ozkul, Tugba Akin Telli, Suleyman Sahin, Saadettin Kilickap, Ahmet Bilici, Bulent Erdogan, Irfan Cicin (2020). Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey. JBUON 2020; 25(4): 1897-1903
A 92. Senem Karabulut, Mehmet Karabulut, Didem Taştekin (2020). What’s new in metastatik colon cancer treatment? Review İstanbul Tıp Fakültesi Dergisi. Doi: 10.26650/İUTFD.2020.0086
A93. Murat Serilmez, Filiz Akyüz, Aslı Örmeci Çiftçibaşı, Senem Karabulut, Sabahattin Kaymakoğlu, Vildan Yasasever, Derya Duranyıldız (2018). Serum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma. Turk J Oncol. 33(1):18–27 Doi: 10.5505/tjo.2018.1742
A 94. Nail Paksoy, Ferhat Ferhatoğlu, İzzet Dogan, Nijat Khanmammadov, Hamza Uğur Bozbey, Senem Karabulut, Didem Tastekin (2022) Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study. Turk J Oncol 2022;37(4):478–83 doi: 10.5505/tjo.2022.3756
A 95. Cigdem Usul Afsar, Hale Aral, Orçun Can, Didem Can Trabulus, Didem Karacetin, Mehmet Ali Nazlı, Rıza Umar Gursu, Senem Karabulut (2023). Serum Fetuin-A and RANKL Levels in Patients with Earlysatage Breast Cancer. Med Biochem 42: 1–9, 2023
A 96. Senem Karabulut, Cigdem U. Afsar, Nail Paksoy, Ferhat Ferhatoglu, Izzet Dogan, Didem Tastekin (2024). Is There Any Diagnostic Value of Seum Caveolin-1 Levels on the Determination of Pancreatic adenocarcinoma? Journal of Cancer Research and Therapeutics. DOI: 10.4103/jcrt.jcrt_469_23
A 97. Sena Şen, Senem Karabulut, Didem Taştekin. The Role of Extracellular Vesicles in Drug Resistance in the 3 Treatment of Metastatic Cancers (2024). Review, Genes, Basım aşamasında.
A 98. Senem Karabulut, Sena Şen, Hilal Oğuz Soydinç, İzzet Doğan, Didem Taştekin, Mehmet Karabulut, Mustafa Duman, Mustafa Turan (2024). Investigation of the potential of miRNA candidates as non-invasive biomarkers for the diagnosis and follow-up of colorectal cancer. Pathology- Research and Practice. Doi: 10.1016/j.prp.2024.155094
A 99. Senem Karabulut, Cigdem Usul Afsar, Nijat Khanmammadov, Latif Karahan, Nail Paksoy, Izzet Dogan, Ferhat Ferhatoglu, Didem Tastekin (2024). Disease characteristics and prognostic factors of colorectal cancer patients with bone metastasis: Areal-world data from Turkey. Journal of Cancer Research and Therapeutics. Doi: 10.410/jcrt.jcrt_392_23
A.100. Nebi Serkan Demirci, Abdulmunir Azizy, Nail Paksoy, İzzet Doğan, Senem Karabulut, Latif Karahan, Didem Tastekin (2024) Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a firstline chemotherapy regimen in her 2-negative metastatic gastric cancer patients A retrospective study. Medicine. Medicine 103(9):37259, 2024. Doi: 10.1097/MD.000000000003725
A. 101. Ünal Ç, Azizy A, Karabulut S, Taştekin D, Akyıldız A, Yaşar S, Yalçın Ş, Çoban E, Evrensel T, Kalkan Z, Oruç Z, Derin S, Turna ZH, Bayram D, Köş FT, Şendur MAN, Sever N, Ercelep Ö, Seyyar M, Kefeli U, Uygun K, Özçelik M, Ön S, Şanlı UA, Canaslan K, Ünek İT, Yücel KB, Özdemir N, Yazıcı O, Güzel HG, Salim DK, Göksu SS, Tatlı AM, Ordu Ç, Selvi O, Sakin A, Büyükbayram ME, Dursun B, Ürün Y, Arak H, Ağdaş G, Uğraklı M, Hendem E, Eryılmaz MK, Bilgin B, Topçu A, Şimşek M, Büyükşimşek M, Akay B, Erdal GŞ, Karataş F, Alan Ö, Çağlayan M, Kahvecioğlu FA, Demirci A, Paksoy N, Çetin B, Gümüş M, Ak N, Aydınalp Y, Paydaş S, Güven DC, Kılıçkap S, Sağlam S (2023). Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group. Oncologist. 2023 3;28(10):875-884. doi: 10.1093/oncolo/oyad257.
A.102. Köstek O, Demirel A, Hacıoğlu MB, Tastekin D, Karabulut S, Gündogdu A, Sever N, Ayhan M, Çelebi A, Majidova N, Yaşar A, Ağyol Y, Erel P, Kocaaslan E, Güren AK, Arıkan R, Isık S, Ercelep O, Goksu SS, Alandag C, Bilgetekin İ, Caner B, Sahin AB, Gulmez A, Akagunduz B, Kose F, Kaplan MA, Dogan E, Sakalar T, Guven DC, Gurbuz M, Ergun Y, Karaagac M, Turker S, Ozkul O, Yıldız B, Sahin S, Demiray AG, Sari M, Erdogan B, Hacıbekiroglu İ, Çakmak Öksüzoğlu ÖB, Kilickap S, Bilici A, Bayoglu İV, Topaloglu S, Cicin İ (2024). The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing. J Chemother. 2024 ;36(7):613-621. doi: 10.1080/1120009X.2024.2305066.

B. Uluslararası bildiri-poster sunumu:
B1. Karabulut S, Serilmez M, Soydinc Oguz H, Duranyıldız D (2016). Do serum nestin levels have a diagnostic effect in patients with colorectal cancer? The FEBS Journal 283 (suppl.1) (2016) 58-123, p:115, Proceeding
B2. Dogan I, Gürbüz M, Aydın E, Tastekin D, Karabulut S, Utkan G (2020). Evaluation of the relationship between ABO blood groups and Her2 positive gastric cancer. 10th International Gastrointestinal Cancers Virtual Conference, 2-6 December 2020, OP-26
B3. Dogan I, Paksoy N, Karabulut S (2020). Small bowel adenocarcinoma: A retrospective analysis. 10th International Gastrointestinal Cancers Virtual Conference, 2-6 December 2020, OP-27
B4. C. Erol, T. Basoglu, A. Sakin, E. Ozden, D. Cubuk, P. Yumuk, M. Dogan, B. Oksuzoglu, H. Yildirim, I. Oner, M. Karakurt Eryilmaz, O. Dulgar, E. Turkmen Bekmez, N. Dogan, M. Ozen, F. Gurler, S. Karabulut, A. Aksoy, M. Hizal, M. Sendur (2021). Efficacy and Safety of Perioperative FLOT (5-FU, LV, Oxaliplatin, Docetaxel) Chemotherapy in Gastric and Gastroesophageal Junction Adenocarcinoma: Real-life Data from Turkish Oncology. ESMO 2021-1405P
B5. Dogan I, Tastekin D, Karabulut S, Sakar B (2021). The efficacy of temozolamid and capecitabine (CAPTEM) combination in metastatik gastrointestinal neuroendocrine tumors. ASCO-GI-2021: Abstract no: 322585, P: 366
B6. Yekedüz E, Dogan I, Akbulut H, Karabulut S, Utkan G, Urun Y (2021). Clinicopathological factors affecting reccurence-free survival in operable gastric cancer patients: A multicenter study. ASCO-GI-2021: Abstract no: 32262, P: 185
B7. Karabulut S, Dogan I, Afsar Usul C, Karabulut M, Karaman S, Ferhatoğlu F, Tastekin D (2020). Does nutritional status affect treatment, tolarebility, response, and survival in metastatic colorectal cancer patients? Results of prospective multicenter study. ASCO GI 2020, DOI: 10.1200/JCO.2020.38.4_suppl.70, Journal of Clinical Oncology 38, no. 4_suppl (February 01, 2020) 70-70. Published online February 04, 2020
B8. Dogan I, Karabulut S, Tastekin D Paksoy N, Şakar B, Vatansever S (2020). Trastuzumab-based treatment of HER2-positive metastatic gastric cancer. ESMO WGI 2020, P-355, S-205
B9. Dogan I, Tastekin D, Sakar B, Karabulut S (2020). Gastrointestinal cancer statistics os a single tertiary oncology centre. 10th International Gastrointestinal Cancers Virtual Conference, 2-6 December 2020, OP-07
B10. S. Karabulut, I. Doğan, C. Usul Afsar, M. Karabulut, D. Taştekin (2019). Does Nutritional Status Affect Treatment Tolarability, Response and Survival in Metastatic Gastric Cancer Patients? Results of Prospective Multicenter Study. ESMO 2019-5063 A, 792P

C. Ulusal hakemli dergilerde yayımlanan makaleler ve kitap bölüm yazarlığı:
C.1 Senem Karabulut, Pınar Saip (2014). Endometrium Kanserinde Kemoterapi. Türkiye Klinikleri Jinekoloji Obstetrik Özel Sayı, 7(3), 100-6.
C.2 Senem Karabulut, Mehmet Karabulut, Cevher Akarsu, Mehmet Abdussamet Bozkurt, Süleyman Bademler, Ali Kocataş, Sema Basat, Halil Alış (2015). Türk Toplumunda Organik Ve Fonksiyonel Dispepsili Hastalarda Etyolojiye Yönelik Analiz. Bakırköy Tıp Dergisi, 11(1), 17-23. Doi: 10.5350/BTDMJB201511105.
C.3 Senem Karabulut, Meltem Ekenel, Ayça İribaş, Emin Darendeliler, Mert Başaran, Sevil Bavbek (2015). Sunitinib ile Tedavi Edilen Metastatik Böbrek Hücreli Karsinom Hastalarinin Klinik Olarak Değerlendirilmesi: Tek Merkez Deneyimi. Türk Onkoloji Dergisi, 30(2), 51-60. Doi: 10.5505/tjoncol.2015.1288.
C.4 Senem Karabulut, Mehmet Karabulut, Çiğdem Usul Afşar, Halil Alış, Murat Emin Güveli, Mustafa Gökhan Ünsal, Fatma Aydoğan, Elif Bilgin, Faruk Taş (2015). Pankreatik Adenokanserde Sirkülasyondaki Proinflamatuar Sitokin Düzeylerinin Klinik Önemi. İstanbul Tıp Fakültesi Dergisi, 78 (4), 102-109.
C.5 Senem Karabulut, Mehmet Karabulut, Halil Alış, Nergiz Dağoğlu, Makbule Tambaş, Selin Kapan, Ebru Oran, Hilal Oğuz, Faruk Taş (2016). Pankreas Adenokanserli Hastalarda Serum Ekstrasellüler Matriks Proteinlerinin Prognostik ve Prediktif Değerinin Araştırılması. Bakırköy Tıp Dergisi, 12(1), 24-32. Doi: 10.5350/BTDMJB201612105
C.6. Senem Karabulut, Mehmet Karabulut, Halil Alış, Makbule Tambaş, Selin Kapan, Osman Köneş, Şule Karaman, Murat Serilmez, Faruk Taş (2016). Pankreas Adenokarsinomunda Serum Tenascin-C Düzeyi Potansiyel Bir Biyobelirteç midir? Bakırköy Tıp Dergisi, 12, 76-82. Doı: 10.5350/BTDMJB201612205
C.7 Senem Karabulut, Mehmet Karabulut, Çiğdem Usul Afşar, Halil Alış, Nergiz Dağoğlu, Cevher Akarsu, Kayhan Ertürk, Elif Bilgin, Faruk Taş (2016). Pankreas Adenokarsinomlu Hastalarda Serum Transforme Edici Büyüme Factor Beta 1 (TGF-B1) Düzeyleri. İstanbul Tıp Fakültesi Dergisi, 79 (1), 9-15.
C.8 Safiye Tokgöz Özal, Ayşegül Akdoğan Gemici, Ercan İnci, Senem Karabulut (2019). 3.0 Tesla Diffüzyon Tensor MR Görüntüleme Parametreleri ile Meme Kanseri Subtipleri Arasındaki İlişkinin Değerlendirilmesi. Kanuni Sultan Süleyman Tıp Dergisi. 11 (1):37-42. Doi:10.5222/iksstd.2019.41275
C.9 Dogan I, Karabulut S. HER2 pozitif metastatic mide kanserli hastalarda sisplatin ve oksaliplatin bazlı tedavilerin karşılaştırılması. Fırat Tıp Dergisi/Firat Med J 2023; 28(4): 252-256,

D. Ulusal Kongrelerde Bildiri/Posterler:
D1. İzzet Doğan, Didem Taştekin, Senem Karabulut (2019). Trigeminal Schwannoma ve Nöroendokrin Tümör Birilikteliği Olgu Sunumu. Ulusal Kanser Kongresi, 2019
D2. İzzet Doğan, Burak Şakar, Gizem Kaval, Didem Taştekin, Senem Karabulut, Kamuran İbiş (2019). Mide, Kolon ve Bilateral Orbital Metastazlı Okült Meme Kanseri Olgu Sunumu. Ulusal Kanser Kongresi, 2019
D3. İzzet Doğan, Nail Paksoy, Didem Taştekin, Senem Karabulut, Metin Pehlivan (2019). İmatinib İlişkili Ciddi Cilt Toksisitesi İki Olgu Sunumu. Ulusal Kanser Kongresi, 2019
D4. Nail Paksoy, İzzet Doğan, Senem Karabulut, Didem Taştekin (2021). Metastatik Mide Kanserinin Birinci Basamak Tedavisinde 5-FU, Oksaliplatin ve Dosetaksel (FLOT) Rejimin Etkinliği. Türk Tıbbi Onkoloji Kongresi, 2021.
H. Kitap Bölüm Yazarlığı:
H1. Murat Sarı, Senem Karabulut (2019). İmmünoterapi. Onkoloji Hemşireliği Kitabı, Nobel Tıp Kitapevi, 2. Baskı, Kısım III Kanserde Tanı ve Tedavi, Bölüm 16, Sayfa 189-193
H2. Senem Karabulut, Ferhat Ferhatoğlu (2021). Kanser Gelişen Fankoni Anemi Hastalarında Kemoterapi Modifikasyonları, Türkiye Klinikleri Özel Sayısı, Yalman N, Editör, p 121-126.
Araştırmacı Olarak Çalıştığı Protokoller:
A two-cohort, open-label, multicenter, study of trastuzumab emtansine (T-DM-1) in HER2 positive locally advanced or metastatic breast cancer patients who have recevied prior anti-HER2 and chemotherapy-based treatment (MO28231) –Yardımcı Araştırmacı (2015-Tamamlandı).
0140346 protokol numaralı, “RECITE-Gastrointestinal, Pankreatik veya Kolorektal Kanserin Tedavisi için Oksaliplatin bazlı Kemoterapi Alan Hastalarda Kemoterapiye Bağlı Trombositopeninin Tedavisinde Romiplostimi Değerlendiren Faz 3, Randomize Plasebo Kontrollü, Çift Kör Çalışma” başlıklı klinik araştırma Yardımcı Araştırmacı
Endocan, PDGF ve Fibrinojen düzeylerinin gastrointestinal kanserli hastalarda prognostik önemi ve bevasizumab ve aflibercept yanıtı ile ilişkisi- BAP projesi-2020-Proje ID: 37036, Proje Kodu: TSA-2020-37036
Kolorektal Kanserli Hastaların Kan Örneklerinde Let-7, miRNA125b ve miRNA30a Seviyelerinin Araştırılması. Sağlık Bilimleri Üniversitesi BAP projesi-2022-Proje No:2022/025
Subject with Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies, Phase I, BNT321 (MVT 5873), Proje yürütücüsü

Nişantaşı Üniversitesi Meslek Yüksekokulu Radyoterapi bölümünde 2015-2016 Eğitim-Öğretim Akademik yılında Temel Onkoloji Dersi
Nişantaşı Üniversitesi Meslek Yüksekokulu Radyoterapi bölümünde 2015-2016 Eğitim-Öğretim Akademik yılında Radyasyon Onkolojisi Dersi
Sağlık Bilimleri Üniversitesi, Bakırköy Dr Sadi Konuk Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği 2015-2016, 2016-2017, 2017-2018 Eğitim-Öğretim Yıllarında Tıbbi Onkoloji Yan Dal Eğitimi
İstanbul Tıp Fakültesi 4. Sınıf öğrenci dersi, Primeri Bilinmeyen Kanserlere Yaklaşım (Türkçe ve İngilizce tıp öğrencilerine)
İstanbul Tıp Fakültesi 4. Sınıf öğrenci dersi, Kanser kinetiği ve kemoterapi prensipleri (Türkçe ve İngilizce tıp öğrencilerine)
İstanbul Onkoloji Enstitüsü, Temel Onkoloji, Yüksek Lisans/Doktora dersi, Kolorektal kanser